BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

October 8, 2012 7:00 AM UTC

AB Science S.A. (Euronext:AB) gained €1.52 (15%) to €11.50 after announcing EMA accepted for review an MAA for masitinib to treat Gleevec-resistant gastrointestinal stromal tumors (GIST).

Basilea Pharmaceutica AG (SIX:BSLN) was up CHF1.10 to CHF48.05 on Friday after announcing an MAA for pneumonia product ceftobiprole was accepted for review under Europe's decentralized procedure. Basilea did not disclose the reference member state conducting the review. The stock gained CHF0.55 on the week...